Guaranteed Safe Checkout

Abbott BinaxNOW Covid-19 Antigen Self-Test- 4 Tests Per Kit

Shipping calculated at checkout.

Vendor: Abbott Laboratories

Size: 1 Kit - 4 Tests
Get FREE SHIPPING if the cart amount is more than $199.00
Shipping calculator

Guaranteed Safe Checkout


Brand: BinaxNOW

UPC: 811877011408

NDC: 11877001140

The Abbott BinaxNOW COVID-19 Antigen Test is designed to identify active infection, whether symptoms are present or not. This fast-result test is suitable for personal use and provides outcomes within 15 minutes or less. Each package contains 2 tests, recommended for situations involving repeated testing. In cases of negative results, serial testing is advised. For individuals with symptoms, testing should be carried out a minimum of twice over three days (with at least a 48-hour gap between tests). For those without symptoms, testing should occur at least thrice over five days (with at least a 48-hour gap between tests).

1 COVID-19 SELF TEST IN THE USA: Made with the same reliable technology used by doctors. Detects multiple COVID-19 variants, including Delta and Omicron*

FAST RESULTS: At home test with results for you or your family in 15 minutes; no need for a prescription or sending to a lab.

TRUSTED TECHNOLOGY: Identical to the test used by professionals; intended for personal use with self-reported results and has Emergency Use Authorization from the FDA

CONVENIENTLY TEST AT HOME: 2 nasal swab tests are included to detect active infection, with or without symptoms.

OR AGES 2 TO ADULT: For children as young as 2 years old when administered by an adult, and for all people 15 and older to self-administer.

The BinaxNOW™ COVID-19 Antigen Self-Test has not been FDA cleared or approved. It has been authorized by the FDA under an emergency use authorization. It has been authorized only for the detection of proteins from SARSCoV-2, not for any other viruses or pathogens, and is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug and Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or authorization is revoked sooner.